{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"77.8","upperLimit":"93.4","value":"87.7"},{"groupId":"OG001","lowerLimit":"80.4","upperLimit":"94.7","value":"89.7"}]}],"title":"24 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65.9","upperLimit":"85.6","value":"77.5"},{"groupId":"OG001","lowerLimit":"70.1","upperLimit":"88.4","value":"81.1"}]}],"title":"36 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"61.6","upperLimit":"82.8","value":"73.9"},{"groupId":"OG001","lowerLimit":"70.1","upperLimit":"88.4","value":"81.1"}]}],"title":"48 Months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"102"}],"units":"Participants"}],"description":"Estimated percentage of participants who were event-free based on Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants diagnosed with WM with mutated MYD88 gene received 420 mg ibrutinib once daily orally until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor","id":"OG000","title":"Arm A: Ibrutinib"},{"description":"Participants diagnosed with WM with mutated MYD88 gene received 160 mg zanubrutinib twice daily orally until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor","id":"OG001","title":"Arm B: Zanubrutinib"}],"paramType":"NUMBER","populationDescription":"ITT Analysis Set","reportingStatus":"POSTED","timeFrame":"24,36 and 48 months from the date of randomization (up to approximately 5 years and 5 months)","title":"DOR as Assessed by the Investigator: Event-Free Rate","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}